Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.
Solanezumab is a humanized anti-amyloid Ξ² monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD).
Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD.
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial.
Ponezumab (PF-04360365) is a humanized anti-amyloid beta (AΞ²) monoclonal antibody designed for treatment of Alzheimer disease (AD).
.
